Print

Active Biotech AB Interim report January - March 2010

2010-04-22

· Laquinimod ― Teva extends its marketing and distribution rights for laquinimod

· TASQ ― preparations for Phase III trials under way

· ANYARA ― exploratory combination data presented

· 57-57 ― exploratory clinical trial in progress

· ISI ― project proceeding according to plan

· RhuDex(TM) ― preclinical studies in progress

· Net sales of SEK 2.8 M (2.2)

· Operating loss of SEK 51.0 M (loss: 63.7)

· Loss after tax of SEK 53.5 M (loss: 62.2)

· Loss per share for the period amounted to SEK 0.83 (loss: 1.21)

· After the end of the period a directed share issue raised approximately SEK 149 M for the company

For further information, please contact:


Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg

VP Investor Relations & Business Development

Tel: +46 (0)46-19 11 54

Hans Kolam

CFO

Tel: +46 (0)46-19 20 44

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 (0)46-19 20 00

Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech Interim report January-March 2010



Back